Literature DB >> 11335886

Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo.

G G Ortiz1, M E Crespo-López, C Morán-Moguel, J J García, R J Reiter, D Acuña-Castroviejo.   

Abstract

OBJECTIVES: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that induces a Parkinsonian-type syndrome in animals which is similar to Parkinson's disease in humans. MPTP toxicity partially depends on the production of free radicals which in turn play a key role in the apoptotic death of neurons. In the present study melatonin, a potent free radical scavenger with antiapoptotic properties, was given to determine whether it would reduce oxidative stress in mice treated with MPTP.
MATERIALS AND METHODS: Male mice were given MPTP with or without melatonin and the brain was studied either 6h, 24h, 7 days or 15 days after the last MPTP injection.
RESULTS: The results show that melatonin counteracted in vivo MPTP-induced apoptosis in midbrain neurons at 6 and 24 h after MPTP treatment, and partially prevented apoptosis at 7 and 15 days after MPTP administration. MPTP treatment also produced time-dependent cell damage, whereas melatonin reduced the percentage of damaged cells at all time points, the effect being most evident at 15 days after treatment. Moreover, melatonin counteracted MPTP-dependent DNA fragmentation in the midbrain and striatum at 7 and 15 days after drug administration.
CONCLUSION: These results support a role for melatonin in protecting neurons against MPTP toxicity in vivo, and suggest that its antiapoptotic action is one of the mechanisms by which melatonin protects neuronal cells from neurotoxic insults.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11335886

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  11 in total

1.  Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation.

Authors:  Ling-Yan Su; Hao Li; Li Lv; Yue-Mei Feng; Guo-Dong Li; Rongcan Luo; He-Jiang Zhou; Xiao-Guang Lei; Liang Ma; Jia-Li Li; Lin Xu; Xin-Tian Hu; Yong-Gang Yao
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

Review 2.  Melatonin and Parkinson's disease.

Authors:  Juan C Mayo; Rosa M Sainz; Dun-Xian Tan; Isaac Antolín; Carmen Rodríguez; Russel J Reiter
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 3.  Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?

Authors:  Naveen Kumar Singhal; Garima Srivastava; Sonal Agrawal; Swatantra Kumar Jain; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2011-12-24       Impact factor: 5.590

Review 4.  Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting.

Authors:  N Zisapel
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

Review 5.  Sleep disorders and fibromyalgia.

Authors:  Suely Roizenblatt; Nilton Salles Rosa Neto; Sergio Tufik
Journal:  Curr Pain Headache Rep       Date:  2011-10

6.  Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine.

Authors:  Genaro Gabriel Ortiz; Fermín P Pacheco-Moisés; Víctor M Gómez-Rodríguez; Erika D González-Renovato; Erandhis D Torres-Sánchez; Ana C Ramírez-Anguiano
Journal:  Metab Brain Dis       Date:  2013-05-24       Impact factor: 3.584

Review 7.  The antiapoptotic activity of melatonin in neurodegenerative diseases.

Authors:  Xin Wang
Journal:  CNS Neurosci Ther       Date:  2009-10-10       Impact factor: 5.243

8.  Melatonin combats molecular terrorism at the mitochondrial level.

Authors:  Russel J Reiter; Sergio D Paredes; Ahmet Korkmaz; Mei-Jie Jou; Dun-Xian Tan
Journal:  Interdiscip Toxicol       Date:  2008-09

9.  The role of mitochondria in brain aging and the effects of melatonin.

Authors:  Germaine Escames; Ana López; José Antonio García; Laura García; Darío Acuña-Castroviejo; José Joaquín García; Luis Carlos López
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

10.  Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis.

Authors:  Ana Luisa Gutierrez-Valdez; Verónica Anaya-Martínez; José Luis Ordoñez-Librado; Ricardo García-Ruiz; Carmen Torres-Esquivel; Montserrat Moreno-Rivera; Javier Sánchez-Betancourt; Enrique Montiel-Flores; Maria Rosa Avila-Costa
Journal:  ISRN Neurol       Date:  2012-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.